The molecules and pathways of the gut-brain axis represent new targets for developing methods to diagnose and treat psychiatric disorders. Manipulation of the gut microbiome with probiotics may be a therapeutic strategy with the potential to relieve gastrointestinal (GI) comorbidities and improve psychiatric symptoms. Candida albicans and Saccharomyces cerevisiae, commensal yeast species, can be imbalanced in the unhealthy human microbiome, and these fungal exposures were previously found elevated in schizophrenia. In a longitudinal, double-blind, placebo-controlled, pilot investigation of 56 outpatients with schizophrenia, we examined the impact of probiotic treatment on yeast antibody levels, and the relationship between treatment and antibody levels on bowel discomfort and psychiatric symptoms. We found that probiotic treatment significantly reduced C. albicans antibodies over the 14-week study period in males, but not in females. Antibody levels of S. cerevisiae were not altered in either treatment group. The highest levels of bowel discomfort over time occurred in C. albicans-seropositive males receiving the placebo. We observed trends towards improvement in positive psychiatric symptoms in males treated with probiotics who were seronegative for C. albicans. Results from this pilot study hint at an association of C. albicans seropositivity with worse positive psychiatric symptoms, which was confirmed in a larger cohort of 384 males with schizophrenia. In conclusion, the administration of probiotics may help normalize C. albicans antibody levels and C. albicans-associated gut discomfort in many male individuals. Studies with larger sample sizes are warranted to address the role of probiotics in correcting C. albicans-associated psychiatric symptoms.
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Introduction
In mental health research, understanding how the gut-brain axis might be altered could aid the development of novel primary and adjunctive therapies for neuropsychiatric disorders such as schizophrenia. Although gastrointestinal (GI) inflammation and dysbioses have been identified as comorbidities in schizophrenia (Castro-Nallar et al., 2015; Severance et al., 2012 Severance et al., , 2013 Yolken et al., 2015; Fond et al., 2015) , treatment trials of gut microbiome modulators such as probiotics are limited. In one of the first published randomized, placebo-controlled trials of probiotic supplementation in outpatients diagnosed with schizophrenia, we previously reported the amelioration of GI functioning in many patients receiving the probiotic treatment (Dickerson et al., 2014) . Analysis of blood samples obtained from individuals in this cohort found significant alterations in immune proteins and associated pathways between treatment groups, which were suggestive of a probiotic-mediated improvement of GI epithelial and immune pathologies (Tomasik et al., 2015) .
Preclinical investigations of the gut-brain axis have largely focused on characterizing how gut bacteria may modulate brain function via immune, neuronal and endocrine pathways (Cryan and Dinan, 2012; Yarandi et al., 2016) . However, other organisms, including fungi, are also components of the human microbiome and these taxa likely contribute to inter-and intra-kingdom dynamics of resident commensals (Ghannoum et al., 2010; Suhr and Hallen-Adams, 2015) . We have previously demonstrated that exposure to members of the human mycobiome, the yeast species, Candida albicans and Saccharomyces cerevisiae, was elevated in indi-
